Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Jones

Showing results (131-140 of 151) with videos related to

Pageof 16
Sort By:
BJU International|July 7, 2018
Patient-reported outcomes of blue-light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre studyAngela B Smith, Siamak Daneshmand, Sanjay Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2017
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaSteven E Coutré, Richard R Furman, Ian W Flinn, et al.
Urologic Oncology|June 24, 2022
Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center studyKamal S Pohar, Sanjay Patel, Yair Lotan, et al.
Blood|July 9, 2014
PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLLDalia El-Gamal, Katie Williams, Taylor D LaFollette, et al.
Mabs|July 26, 2013
Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignanciesSarwish Rafiq, Anthony Siadak, Jonathan P Butchar, et al.
The Journal of Pain|March 11, 2023
CpG Methylation Levels in HPA Axis Genes Predict Chronic Pain Outcomes Following Trauma ExposureErica M Branham, Samuel A McLean, Ishani Deliwala, et al.
BMJ Open|September 8, 2016
Methodology of AA CRASH: a prospective observational study evaluating the incidence and pathogenesis of adverse post-traumatic sequelae in African-Americans experiencing motor vehicle collisionSarah D Linnstaedt, JunMei Hu, Andrea Y Liu, et al.
Psychological Medicine|July 1, 2022
Derivation and validation of risk prediction for posttraumatic stress symptoms following trauma exposureRaphael Kim, Tina Lin, Gehao Pang, et al.
Mabs|December 12, 2017
Productive common light chain libraries yield diverse panels of high affinity bispecific antibodiesThomas Van Blarcom, Kevin Lindquist, Zea Melton, et al.
Blood|January 14, 2014
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapyJennifer A Woyach, Kelly Smucker, Lisa L Smith, et al.
Pageof 16

Showing results (131-140 of 151) with videos related to

Sort By:
Pageof 16
BJU International|July 7, 2018
Patient-reported outcomes of blue-light flexible cystoscopy with hexaminolevulinate in the surveillance of bladder cancer: results from a prospective multicentre studyAngela B Smith, Siamak Daneshmand, Sanjay Patel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2017
Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaSteven E Coutré, Richard R Furman, Ian W Flinn, et al.
Urologic Oncology|June 24, 2022
Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center studyKamal S Pohar, Sanjay Patel, Yair Lotan, et al.
Blood|July 9, 2014
PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLLDalia El-Gamal, Katie Williams, Taylor D LaFollette, et al.
Mabs|July 26, 2013
Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignanciesSarwish Rafiq, Anthony Siadak, Jonathan P Butchar, et al.
The Journal of Pain|March 11, 2023
CpG Methylation Levels in HPA Axis Genes Predict Chronic Pain Outcomes Following Trauma ExposureErica M Branham, Samuel A McLean, Ishani Deliwala, et al.
BMJ Open|September 8, 2016
Methodology of AA CRASH: a prospective observational study evaluating the incidence and pathogenesis of adverse post-traumatic sequelae in African-Americans experiencing motor vehicle collisionSarah D Linnstaedt, JunMei Hu, Andrea Y Liu, et al.
Psychological Medicine|July 1, 2022
Derivation and validation of risk prediction for posttraumatic stress symptoms following trauma exposureRaphael Kim, Tina Lin, Gehao Pang, et al.
Mabs|December 12, 2017
Productive common light chain libraries yield diverse panels of high affinity bispecific antibodiesThomas Van Blarcom, Kevin Lindquist, Zea Melton, et al.
Blood|January 14, 2014
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapyJennifer A Woyach, Kelly Smucker, Lisa L Smith, et al.
Pageof 16